523 related articles for article (PubMed ID: 25687897)
21. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis.
Park H; Park C; Kim Y; Rascati KL
Ann Pharmacother; 2012 Nov; 46(11):1453-69. PubMed ID: 23136353
[TBL] [Abstract][Full Text] [Related]
22. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
Roussel R; Duran-García S; Zhang Y; Shah S; Darmiento C; Shankar RR; Golm GT; Lam RLH; O'Neill EA; Gantz I; Kaufman KD; Engel SS
Diabetes Obes Metab; 2019 Apr; 21(4):781-790. PubMed ID: 30393950
[TBL] [Abstract][Full Text] [Related]
23. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Scheen AJ
Diabetes Metab; 2012 Apr; 38(2):89-101. PubMed ID: 22197148
[TBL] [Abstract][Full Text] [Related]
24. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.
Scheen AJ
Diabetes Metab; 2020 Jun; 46(3):186-196. PubMed ID: 32007623
[TBL] [Abstract][Full Text] [Related]
25. DPP-4 inhibitor treatment: β-cell response but not HbA
Kozlovski P; Bhosekar V; Foley JE
Vasc Health Risk Manag; 2017; 13():123-126. PubMed ID: 28408838
[TBL] [Abstract][Full Text] [Related]
26. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis.
Tricco AC; Antony J; Khan PA; Ghassemi M; Hamid JS; Ashoor H; Blondal E; Soobiah C; Yu CH; Hutton B; Hemmelgarn BR; Moher D; Majumdar SR; Straus SE
BMJ Open; 2014 Dec; 4(12):e005752. PubMed ID: 25537781
[TBL] [Abstract][Full Text] [Related]
27. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
Hollander PA; Kushner P
Postgrad Med; 2010 May; 122(3):71-80. PubMed ID: 20463416
[TBL] [Abstract][Full Text] [Related]
28. Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study.
Ofori-Asenso R; Ilomaki J; Chin KL; Mazidi M; Zomer E; Bell JS; Magliano DJ; Liew D
Diabetes Res Clin Pract; 2019 Dec; 158():107909. PubMed ID: 31697992
[TBL] [Abstract][Full Text] [Related]
29. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
Thayer S; Chow W; Korrer S; Aguilar R
Curr Med Res Opin; 2016 Jun; 32(6):1087-96. PubMed ID: 26938635
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
31. Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
Derosa G; Maffioli P
Diabetes Technol Ther; 2012 Apr; 14(4):350-64. PubMed ID: 22324384
[TBL] [Abstract][Full Text] [Related]
32. Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients.
Ayers D; Kanters S; Goldgrub R; Hughes M; Kato R; Kragh N
Curr Med Res Opin; 2017 Sep; 33(9):1653-1661. PubMed ID: 28635331
[TBL] [Abstract][Full Text] [Related]
33. [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
Kleefstra N; van Hateren KJ; Houweling ST; Verhoeven S; Kooy A; Goudswaard AN; Bilo HJ
Ned Tijdschr Geneeskd; 2010; 154():A886. PubMed ID: 20298625
[TBL] [Abstract][Full Text] [Related]
34. DPP-4 inhibitors: what may be the clinical differentiators?
Gerich J
Diabetes Res Clin Pract; 2010 Nov; 90(2):131-40. PubMed ID: 20708812
[TBL] [Abstract][Full Text] [Related]
35. Observational study on dipeptidyl peptidase-4 inhibitors: a real-life analysis on 360 patients from the ASL VCO territory in Italy.
Saglietti G; Placentino G; Schellino A
Clin Drug Investig; 2014 Jul; 34(7):513-9. PubMed ID: 24788571
[TBL] [Abstract][Full Text] [Related]
36. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
Golightly LK; Drayna CC; McDermott MT
Clin Pharmacokinet; 2012 Aug; 51(8):501-14. PubMed ID: 22686547
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis.
Sharma M; Beckley N; Nazareth I; Petersen I
BMJ Open; 2017 Oct; 7(10):e017260. PubMed ID: 29084794
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Mikhail N
Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
[TBL] [Abstract][Full Text] [Related]
39. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
Rosenstock J; Sankoh S; List JF
Diabetes Obes Metab; 2008 May; 10(5):376-86. PubMed ID: 18355324
[TBL] [Abstract][Full Text] [Related]
40. Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes.
Wang JS; Hung YJ; Lu YC; Tsai CL; Yang WS; Lee TI; Hsiao YC; Sheu WH
Diabetes Res Clin Pract; 2018 Apr; 138():119-127. PubMed ID: 29444447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
